Cited 95 times in
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.